[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

Rhea-AI Filing Summary

United Therapeutics Corporation (UTHR) reported insider activity by its CFO and Treasurer. On November 17, 2025, the officer exercised stock options to acquire 10,688 and 10,312 shares of common stock at an exercise price of $146.03 per share. Most of these shares were then sold the same day in a series of market transactions at weighted average prices ranging from $464.3842 to $476.4706, executed under a pre-arranged Rule 10b5-1 trading plan entered into on August 5, 2025. Following these transactions, the officer directly owns 8,118 shares of United Therapeutics common stock and holds 21,517 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO AND TREASURER

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		M(1)		10,688	A	$146.03	18,806	D
Common Stock	11/17/2025		S(1)		3,591	D	$470.3363(2)	15,215	D
Common Stock	11/17/2025		S(1)		2,657	D	$471.2194(3)	12,558	D
Common Stock	11/17/2025		S(1)		1,999	D	$472.129(4)	10,559	D
Common Stock	11/17/2025		S(1)		920	D	$473.6769(5)	9,639	D
Common Stock	11/17/2025		S(1)		639	D	$474.799(6)	9,000	D
Common Stock	11/17/2025		S(1)		798	D	$475.891(7)	8,202	D
Common Stock	11/17/2025		S(1)		84	D	$476.4706(8)	8,118	D
Common Stock	11/17/2025		M(1)		10,312	A	$146.03	18,430	D
Common Stock	11/17/2025		S(1)		120	D	$464.3842(9)	18,310	D
Common Stock	11/17/2025		S(1)		1,090	D	$467.5252(10)	17,220	D
Common Stock	11/17/2025		S(1)		4,107	D	$468.3284(11)	13,113	D
Common Stock	11/17/2025		S(1)		4,558	D	$469.3916(12)	8,555	D
Common Stock	11/17/2025		S(1)		437	D	$470.3363(2)	8,118	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$146.03	11/17/2025		M(1)			10,312	03/15/2020	03/15/2027	Common Stock	10,312	$0.00	0.00	D
Stock Option	$146.03	11/17/2025		M(1)			10,688	03/15/2020	03/15/2027	Common Stock	10,688	$0.00	21,517	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $469.87 to $470.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $470.88 to $471.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $471.92 to $472.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $473.17 to $474.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $474.34 to $475.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $475.34 to $476.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $476.43 to $476.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $463.67 to $464.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $466.835 to $467.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $467.835 to $468.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $468.84 to $469.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did United Therapeutics (UTHR) report for its CFO?

The CFO and Treasurer of United Therapeutics (UTHR) exercised stock options for 10,688 and 10,312 shares at $146.03 per share and sold most of the resulting shares on November 17, 2025.

At what prices did the UTHR CFO sell United Therapeutics shares on November 17, 2025?

The reported sales were executed in multiple trades at weighted average prices ranging from $464.3842 to $476.4706 per share, with each price reflecting aggregated trades within specified ranges.

Was the United Therapeutics (UTHR) insider trading under a Rule 10b5-1 plan?

Yes. The exercise of options and subsequent share sales were carried out under a Rule 10b5-1 trading plan that the reporting person entered into on August 5, 2025.

How many United Therapeutics (UTHR) shares does the CFO hold after these transactions?

After the reported transactions, the officer directly owns 8,118 shares of United Therapeutics common stock.

How many stock options does the UTHR CFO retain after the reported transactions?

Following the option exercises on November 17, 2025, the officer beneficially owns 21,517 remaining stock options on United Therapeutics common stock.

Why are some United Therapeutics (UTHR) insider sales reported as weighted average prices?

The filing states that several transactions were executed in multiple trades within price ranges (for example, from $469.87 to $470.86), so a weighted average price is reported, with full trade details available upon request.